TY - JOUR
T1 - Molecular heterogeneity in diffuse large B-cell lymphoma and its implications in clinical diagnosis and treatment
AU - Guo, Lingchuan
AU - Lin, Pei
AU - Xiong, Hui
AU - Tu, Shichun
AU - Chen, Gang
N1 - Funding Information:
This work was supported in part by grants from the Fujian Province Natural Fund [ 2016J01512 ] and the Training Project for Young and Middle-Aged Talents of Fujian Provincial Department of Health in China [ 2013-ZQN-ZD-7 ].
Publisher Copyright:
© 2018 Elsevier B.V.
PY - 2018/4
Y1 - 2018/4
N2 - Over half of patients with diffuse large B-cell lymphoma (DLBCL) can be cured by standard R-CHOP treatment (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). However, the remaining patients are refractory and ultimately succumb to progressive or relapsed disease. During the past decade, there has been significant progress in the understanding of molecular mechanisms in DLBCL, largely owing to collaborative efforts in large-scale gene expression profiling and deep sequencing, which have identified genetic alterations critical in lymphomagenesis through activation of key signaling transduction pathways in DLBCL. These discoveries have not only led to the development of targeted therapies, including several currently in clinical trials, but also laid a solid foundation for the future identification of more effective therapies for patients not curable by R-CHOP. This review summarizes the recent advances in our understanding of the molecular characterization and pathogenesis of DLBCL and new treatment directions.
AB - Over half of patients with diffuse large B-cell lymphoma (DLBCL) can be cured by standard R-CHOP treatment (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). However, the remaining patients are refractory and ultimately succumb to progressive or relapsed disease. During the past decade, there has been significant progress in the understanding of molecular mechanisms in DLBCL, largely owing to collaborative efforts in large-scale gene expression profiling and deep sequencing, which have identified genetic alterations critical in lymphomagenesis through activation of key signaling transduction pathways in DLBCL. These discoveries have not only led to the development of targeted therapies, including several currently in clinical trials, but also laid a solid foundation for the future identification of more effective therapies for patients not curable by R-CHOP. This review summarizes the recent advances in our understanding of the molecular characterization and pathogenesis of DLBCL and new treatment directions.
KW - ABC
KW - DLBCL
KW - GCB
KW - Molecular heterogeneity
KW - Targeted therapies
UR - http://www.scopus.com/inward/record.url?scp=85041398841&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85041398841&partnerID=8YFLogxK
U2 - 10.1016/j.bbcan.2018.01.001
DO - 10.1016/j.bbcan.2018.01.001
M3 - Review article
C2 - 29337112
AN - SCOPUS:85041398841
SN - 0304-419X
VL - 1869
SP - 85
EP - 96
JO - Biochimica et Biophysica Acta - Reviews on Cancer
JF - Biochimica et Biophysica Acta - Reviews on Cancer
IS - 2
ER -